Abstract: An application for tracking symptom triggers affecting the microbiome stored on non-transitory computer readable media including an input module for inputting variables from a user in electronic communication with an output variable module, an analysis module for analyzing input variables and output variables, and an output module for presenting results to the user. A method of tracking triggers of symptoms affecting the microbiome in a user, by a user inputting data about nutrition, medication, lifestyle, symptoms due to cancer therapy, pain, and user defined metrics in an application stored on non-transitory computer readable media, performing an analysis on the data, and outputting a result from the data identifying daily activities that effect the user's symptoms and microbiome. A method of adjusting treatment of the microbiome of a patient.

Abstract: An application for tracking disease, pain, and mental health symptom triggers including an input module for inputting variables from a user in electronic communication with an output variable module, an analysis module for analyzing input variables and output variables, and an output module for presenting results to the user, wherein the output module provides notice that it is likely that disease or mental health symptoms will appear. A method of preventing the onset of disease or mental health symptoms, by a user inputting data about nutrition, medication, lifestyle, symptoms, and user defined metrics in an application, performing an analysis on the data, outputting a result from the data identifying daily activities that effect the user's disease/mental health and trigger symptoms, including strongest trends, key performance indicators, and tracking over time, and outputting notice that it is likely that disease or mental health symptoms will appear.

Abstract: A method of eliminating the risk of JCV activation in a subject undergoing immunosuppressive therapy, by administering an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome, cleaving the target sequence in the JCV genome, disrupting the JCV genome, eliminating the JCV infection, eliminating the risk of JCV activation, and treating the subject with an immunosuppressive therapy. A pharmaceutical composition including at least one isolated nucleic acid sequence encoding a CRISPR-associated endonuclease and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA, the isolated nucleic acid sequences being included in at least one expression vector. Pharmaceutical compositions including at least one isolated nucleic acid sequence encoding at least one TALEN, at least one ZFN, and gene editing composition of C2c1, C2c3, TevCas9, Archaea Cas9, CasY.1-CasY.

Abstract: A method of eliminating the risk of JCV activation in a subject undergoing immunosuppressive therapy, by administering an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome, cleaving the target sequence in the JCV genome, disrupting the JCV genome, eliminating the JCV infection, eliminating the risk of JCV activation, and treating the subject with an immunosuppressive therapy. A pharmaceutical composition including at least one isolated nucleic acid sequence encoding a CRISPR-associated endonuclease and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA, the isolated nucleic acid sequences being included in at least one expression vector. Pharmaceutical compositions including at least one isolated nucleic acid sequence encoding at least one TALEN, at least one ZFN, and gene editing composition of C2c1, C2c3, TevCas9, Archaea Cas9, CasY.1-CasY.

Abstract: An application for tracking disease, pain, and mental health symptom triggers including an input module for inputting variables from a user in electronic communication with an output variable module, an analysis module for analyzing input variables and output variables, and an output module for presenting results to the user. A method of tracking disease, pain, and mental health triggers, by a user inputting data about nutrition, medication, lifestyle, symptoms, pain, and user defined metrics in an application, performing an analysis on the data, and outputting a result from the data identifying daily activities that effect the user's disease/mental health and trigger symptoms. A method of preventing adverse events.

Abstract: An application for tracking cancer therapy symptom triggers stored on non-transitory computer readable media including an input module for inputting variables from a user in electronic communication with an output variable module, an analysis module for analyzing input variables and output variables, and an output module for presenting results to the user. A method of tracking triggers of symptoms in cancer patients, by a user inputting data about nutrition, medication, lifestyle, symptoms due to cancer therapy, pain, and user defined metrics in an application stored on non-transitory computer readable media, performing an analysis on the data, and outputting a result from the data identifying daily activities that effect the user's symptoms due to cancer therapy. A method of adjusting treatment of a cancer patient.

Abstract: A method of dosing food and nutrients for an individual patient, by collecting data from the individual patient including food and nutrients to be taken by the patient, analyzing the data in view of dosing criteria established based on outside data, and determining a dose for each food and nutrient taken by the individual patient. A logic engine for dosing food and nutrients, including an algorithm stored on non-transitory computer readable media for collecting outside data to establish criteria for dosing food and nutrients to an individual patient and patient data and storing outside data and patient data in a database, analyzing the individual patient data in view of criteria established from the outside data, and determining a dose for each food and nutrient to be taken.

Abstract: An application for tracking infectious disease including an input module for inputting variables from a user in electronic communication with an output variable module, an analysis module for analyzing input variables and output variables, and an output module for presenting results to the user. A method of tracking infectious disease, by a user inputting data about symptoms of infectious disease and user defined metrics in an application, performing an analysis on the data, and outputting a result from the data tracking symptom progression, tracking geolocation of symptoms and outbreaks, and tracking trends among individuals without symptoms and individuals with different diseases. A method of monitoring the health of employees and students.

Abstract: A method of dosing multiple drugs for an individual patient, by collecting data from the individual patient including drugs to be taken by the patient and genetic testing information, analyzing the individual patient data in view of dosing criteria established based on outside patient data, and determining doses of multiple drugs for each drug taken by the individual patient. A logic engine for dosing multiple drugs, including an algorithm stored on non-transitory computer readable media for collecting outside data to establish criteria for dosing multiple drugs to an individual patient and storing the outside data and individual patient data in a database, analyzing the individual patient data in view of criteria established from the outside data, and determining a dose for each drug to be taken.

Abstract: A method of dosing cancer therapies, by collecting patient data including cancer therapies/drugs to be taken, analyzing the data in view of dosing criteria established based on outside data, and determining a dose for each cancer therapy/drug taken. A logic engine for dosing cancer therapies, including an algorithm stored on non-transitory computer readable media for collecting clinical trial data to establish criteria for dosing cancer therapies/drugs to a single patient and patient data and storing the clinical trial data and patient data in a database, analyzing the patient data in view of criteria established from the clinical trial data, and determining a dose for each cancer therapy/drug. A method of adjusting treatment of a cancer patient.

Abstract: A method and algorithm for dosing single and multiple drugs for an individual patient includes the step of collecting data from the individual patient. The data includes drugs to be taken by the patient, the patient's age, medical condition, metabolism, and other factors. The method further includes the steps of analyzing the individual patient data in view of dosing criteria established based on patient population data. Based on the analysis, a dose of the single or multiple drugs is recommended. Alternative treatment options can also be recommended.

Abstract: A method of eliminating the risk of JCV activation in a subject undergoing immunosuppressive therapy, by administering an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome, cleaving the target sequence in the JCV genome, disrupting the JCV genome, eliminating the JCV infection, eliminating the risk of JCV activation, and treating the subject with an immunosuppressive therapy. A pharmaceutical composition including at least one isolated nucleic acid sequence encoding a CRISPR-associated endonuclease and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA, the isolated nucleic acid sequences being included in at least one expression vector. Pharmaceutical compositions including at least one isolated nucleic acid sequence encoding at least one TALEN, at least one ZFN, and gene editing composition of C2c1, C2c3, TevCas9, Archaea Cas9, CasY.1-CasY.

Abstract: A method of eliminating the risk of JCV activation in a subject undergoing immunosuppressive therapy, by administering an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome, cleaving the target sequence in the JCV genome, disrupting the JCV genome, eliminating the JCV infection, eliminating the risk of JCV activation, and treating the subject with an immunosuppressive therapy. A pharmaceutical composition including at least one isolated nucleic acid sequence encoding a CRISPR-associated endonuclease and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA, the isolated nucleic acid sequences being included in at least one expression vector. Pharmaceutical compositions including at least one isolated nucleic acid sequence encoding at least one TALEN, at least one ZFN, and gene editing composition of C2c1, C2c3, TevCas9, Archaea Cas9, CasY.1-CasY.

Abstract: A method of eliminating the risk of JCV activation in a subject undergoing immunosuppressive therapy, by administering an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome, cleaving the target sequence in the JCV genome, disrupting the JCV genome, eliminating the JCV infection, eliminating the risk of JCV activation, and treating the subject with an immunosuppressive therapy. A pharmaceutical composition including at least one isolated nucleic acid sequence encoding a CRISPR-associated endonuclease and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA, the isolated nucleic acid sequences being included in at least one expression vector. Pharmaceutical compositions including at least one isolated nucleic acid sequence encoding at least one TALEN, at least one ZFN, and gene editing composition of C2c1, C2c3, TevCas9, Archaea Cas9, CasY.1-CasY.

Abstract: A composition for treating inflammation and pain, including a hydrogen-generating compound in an amount that increases the amount of hydrogen in an individual and has an anti-inflammatory effect. A composition for treating inflammation and pain, including synergistically effective amounts of pregabalin and lactulose. A method of treating inflammation and pain, by administering a composition comprising a hydrogen-generating compound to an individual in an amount that increases the amount of hydrogen in the individual and has an anti-inflammatory effect.

Abstract: A composition for treating multiple disease causes including a glycocalyx restoring and maintaining compound. A method of treating multiple disease causes, by administering a glycocalyx restoring and maintaining compound to an individual, restoring the glycocalyx, reversing inflammation, and reversing oxidative damage. A method of treating cardiovascular disease. A method of restoring the glycocalyx. A method of reversing inflammation. A method of reversing oxidative damage. A method of treating any disease involving a membrane that has a glycocalyx. A method of treating multiple disease causes. A method of restoring the structural and functional integrity of receptors in the glycocalyx. A method of restoring the glycocalyx and receptors therein and potentiating drug response. A composition for treating disease including the glycocalyx restoring and maintaining compound and an antibody.

Abstract: A composition for treating multiple disease causes including a glycocalyx restoring and maintaining compound in an oral dosage form. A method of treating cardiovascular disease (CVD), by administering a glycocalyx restoring and maintaining compound to an individual suffering from CVD, restoring the glycocalyx, reversing inflammation, and reversing oxidative damage.

Abstract: A composition for treating multiple disease causes including a glycocalyx restoring and maintaining compound in an oral dosage form. A method of treating cardiovascular disease (CVD), by administering a glycocalyx restoring and maintaining compound to an individual suffering from CVD, restoring the glycocalyx, reversing inflammation, and reversing oxidative damage.

Abstract: A composition for extending the half-life of a crystalline antibody, including synergistically effective amounts of a half-life-extending compound and a crystalline antibody. A composition for extending the half-life of a crystalline antibody including synergistically effective amounts of lactulose and a crystalline anti-PCSK9 antibody. A method of extending the half-life of a crystalline antibody, by administering a synergistically effective amount of a half-life-extending compound and a crystalline antibody to an individual, and extending the half-life of the crystalline antibody. A method of promoting antibody recycling by affecting a receptor for an antibody to recycle the antibody.

Abstract: A composition for treating inflammation and pain, including a hydrogen-generating compound in an amount that increases the amount of hydrogen in an individual and has an anti-inflammatory effect. A composition for treating inflammation and pain, including synergistically effective amounts of pregabalin and lactulose. A method of treating inflammation and pain, by administering a composition comprising a hydrogen-generating compound to an individual in an amount that increases the amount of hydrogen in the individual and has an anti-inflammatory effect.